Harnessing benefit from targeting tumor associated carbohydrate antigens

References

• Colozza M, de Azambuja E, Cardoso F, Bernard C, Piccart MJ. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist 2006; 11:111-25; PMID:16476832; http://dx.doi.org/10.1634/theoncologist.11-2-111
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608:1-22; PMID:17993229; http://dx.doi.org/10.1007/978-0-387-74039-3_1
   PubMed Web of Science ®Google Scholar
• Autier P, Hery C, Haukka J, Boniol M, Byrnes G. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol 2009; 27:5919-23. Epub 2009 Nov 2; PMID:19884547; http://dx.doi.org/10.1200/JCO.2009.22.7041
   PubMed Web of Science ®Google Scholar
• Clay TM, Osada T, Hartman ZC, Hobeika A, Devi G, Morse MA, Lyerly HK. Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. Immunol Res 2011; 49:235-47; PMID:21136201; http://dx.doi.org/10.1007/s12026-010-8186-6
   PubMed Web of Science ®Google Scholar
• Perez-Herrero E, Fernandez-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 2015; 93:52-79. Epub Mar 23; PMID:25813885; http://dx.doi.org/10.1016/j.ejpb.2015.03.018
   PubMed Web of Science ®Google Scholar
• Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 2005; 57:187-215; PMID:15914467; http://dx.doi.org/10.1124/pr.57.2.6
   PubMed Web of Science ®Google Scholar
• Berg EL, Kunkel EJ, Hytopoulos E. Biological complexity and drug discovery: a practical systems biology approach. Syst Biol (Stevenage) 2005; 152:201-6; PMID:16986261; http://dx.doi.org/10.1049/ip-syb:20050036
   PubMedGoogle Scholar
• Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009; 10:1179-87; PMID:19959074; http://dx.doi.org/10.1016/S1470-2045(09)70315-8
   PubMed Web of Science ®Google Scholar
• Ferreira AF, de Oliveira GL, Tognon R, Collassanti MD, Zanichelli MA, Hamerschlak N, de Souza AM, Covas DT, Kashima S, de Castro FA. Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy. Acta Haematol 2015; 133:354-64. Epub 2015 Feb 17; PMID:25721555; http://dx.doi.org/10.1159/000369446
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92; PMID:11248153; http://dx.doi.org/10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Torti D, Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 2011; 3:623-36. Epub 2011 Sep 23; PMID:21953712; http://dx.doi.org/10.1002/emmm.201100176
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction–a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006; 3:448-57; PMID:16894390; http://dx.doi.org/10.1038/ncponc0558
   PubMedGoogle Scholar
• Topol EJ. Individualized medicine from prewomb to tomb. Cell 2014; 157:241-53; PMID:24679539; http://dx.doi.org/10.1016/j.cell.2014.02.012
   PubMed Web of Science ®Google Scholar
• Kitano H. Systems biology: a brief overview. Science 2002; 295:1662-4; PMID:11872829; http://dx.doi.org/10.1126/science.1069492
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res 2004; 32:D277-80; PMID:14681412; http://dx.doi.org/10.1093/nar/gkh063
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-65; PMID:11357143; http://dx.doi.org/10.1038/35077225
   PubMed Web of Science ®Google Scholar
• Mao YJ, Li HH, Li JF, Shen JS. [Signal transduction by protein tyrosine kinases and antitumor agents]. Yao Xue Xue Bao 2008; 43:323-34; PMID:18664191
   PubMedGoogle Scholar
• Brent R. Genomic biology. Cell 2000; 100:169-83; PMID:10647941; http://dx.doi.org/10.1016/S0092-8674(00)81693-1
   PubMed Web of Science ®Google Scholar
• Zhang P. The cell cycle and development: redundant roles of cell cycle regulators. Curr Opin Cell Biol 1999; 11:655-62; PMID:10600701; http://dx.doi.org/10.1016/S0955-0674(99)00032-0
   PubMed Web of Science ®Google Scholar
• Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, et al. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 2001; 61:1464-8; PMID:11245452
   PubMed Web of Science ®Google Scholar
• Hoekman K. SU6668, a multitargeted angiogenesis inhibitor. Cancer J 2001; 7:S134-8; PMID:11779084
   PubMedGoogle Scholar
• Yau T, Dan X, Ng CC, Ng TB. Lectins with potential for anti-cancer therapy. Molecules 2015; 20:3791-810; PMID:25730388; http://dx.doi.org/10.3390/molecules20033791
   PubMed Web of Science ®Google Scholar
• Peng Y, Kowalewski R, Kim S, Elkon KB. The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol Immunol 2005; 42:781-7. Epub 2005 Jan 16; PMID:15829266; http://dx.doi.org/10.1016/j.molimm.2004.07.045
   PubMed Web of Science ®Google Scholar
• Varambally S, Bar-Dayan Y, Bayry J, Lacroix-Desmazes S, Horn M, Sorel M, Bar-Dayan Y, Ruberti G, Kazatchkine MD, Kaveri SV. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int Immunol 2004; 16:517-24; PMID:14978025; http://dx.doi.org/10.1093/intimm/dxh053
   PubMed Web of Science ®Google Scholar
• Vollmers HP, Brandlein S. Natural antibodies and cancer. N Biotechnol 2009; 25:294-8. Epub Apr 11; PMID:19442595; http://dx.doi.org/10.1016/j.nbt.2009.03.016
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Nishiura H, Yamamoto T. Requirement of the acquired immune system in successful cancer chemotherapy with cis-diamminedichloroplatinum (II) in a syngeneic mouse tumor transplantation model. J Immunother 2011; 34:480-9; PMID:21654518; http://dx.doi.org/10.1097/CJI.0b013e31821e7662
   PubMed Web of Science ®Google Scholar
• Garg AD, Dudek-Peric AM, Romano E, Agostinis P. Immunogenic cell death. Int J Dev Biol 2015; 59:131-40; PMID:26374534; http://dx.doi.org/10.1387/ijdb.150061pa
   PubMed Web of Science ®Google Scholar
• Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L, et al. Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front Immunol 2015; 6:402. eCollection 2015; PMID:26300886; http://dx.doi.org/10.3389/fimmu.2015.00402
   PubMed Web of Science ®Google Scholar
• Lorusso G, Ruegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 2012; 22:226-33. Epub Apr 5; PMID:22504658; http://dx.doi.org/10.1016/j.semcancer.2012.03.007
   PubMed Web of Science ®Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237-51; PMID:22437869; http://dx.doi.org/10.1038/nrc3237
   PubMed Web of Science ®Google Scholar
• Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 2013; 73:2943-8. Epub 2013 Feb 25; PMID:23440426; http://dx.doi.org/10.1158/0008-5472.CAN-12-4354
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 2015; 3:436-43; PMID:25941355; http://dx.doi.org/10.1158/2326-6066.CIR-15-0064
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar R, Bakker J, van Bueren JJ, Parren PW, Lokhorst HM, van de Donk NW, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res 2015; 21:2802-10. Epub 2014 Nov 14; PMID:25398450; http://dx.doi.org/10.1158/1078-0432.CCR-14-1813
   PubMed Web of Science ®Google Scholar
• van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011; 96:284-90. Epub 2010 Nov 25; PMID:21109694; http://dx.doi.org/10.3324/haematol.2010.030759
   PubMed Web of Science ®Google Scholar
• Kim JE, Jin DH, Lee WJ, Hur D, Wu TC, Kim D. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells. Pharmacol Res 2013; 71:23-33. Epub Feb 18; PMID:23428347; http://dx.doi.org/10.1016/j.phrs.2013.02.001
   PubMed Web of Science ®Google Scholar
• Lichtenstein RG, Rabinovich GA. Glycobiology of cell death: when glycans and lectins govern cell fate. Cell Death Differ 2013; 20:976-86. Epub May 24; PMID:23703323; http://dx.doi.org/10.1038/cdd.2013.50
   PubMed Web of Science ®Google Scholar
• Ma J, Hart GW. O-GlcNAc profiling: from proteins to proteomes. Clin Proteomics 2014; 11:8; PMID:24593906; http://dx.doi.org/10.1186/1559-0275-11-8
   PubMed Web of Science ®Google Scholar
• Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem 2011; 80:825-58; PMID:21391816; http://dx.doi.org/10.1146/annurev-biochem-060608-102511
   PubMed Web of Science ®Google Scholar
• Chaiyawat P, Netsirisawan P, Svasti J, Champattanachai V. Aberrant O-GlcNAcylated proteins: new perspectives in breast and colorectal cancer. Front Endocrinol (Lausanne) 2014; 5:193. eCollection 2014; PMID:25426101
   PubMed Web of Science ®Google Scholar
• Hirano K, Matsuda A, Shirai T, Furukawa K. Expression of LacdiNAc groups on N-glycans among human tumors is complex. Biomed Res Int 2014; 2014:981627. Epub 2014 May 18; PMID:25003135; http://dx.doi.org/10.1155/2014/981627
   PubMed Web of Science ®Google Scholar
• Kim M, Rao MV, Tweardy DJ, Prakash M, Galili U, Gorelik E. Lectin-induced apoptosis of tumour cells. Glycobiology 1993; 3:447-53; PMID:8286857; http://dx.doi.org/10.1093/glycob/3.5.447
   PubMed Web of Science ®Google Scholar
• Lyu SY, Choi SH, Park WB. Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p53. Arch Pharm Res 2002; 25:93-101; PMID:11885700; http://dx.doi.org/10.1007/BF02975269
   PubMed Web of Science ®Google Scholar
• Choi SH, Lyu SY, Park WB. Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of Akt. Arch Pharm Res 2004; 27:68-76; PMID:14969342; http://dx.doi.org/10.1007/BF02980049
   PubMed Web of Science ®Google Scholar
• Valenzuela HF, Pace KE, Cabrera PV, White R, Porvari K, Kaija H, Vihko P, Baum LG. O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1. Cancer Res 2007; 67:6155-62; PMID:17616672; http://dx.doi.org/10.1158/0008-5472.CAN-05-4431
   PubMed Web of Science ®Google Scholar
• Zheng T, Jiang H, Gros M, del Amo DS, Sundaram S, Lauvau G, Marlow F, Liu Y, Stanley P, Wu P. Tracking N-acetyllactosamine on cell-surface glycans in vivo. Angew Chem Int Ed Engl 2011; 50:4113-8. Epub 2011 Mar 29; PMID:21472942; http://dx.doi.org/10.1002/anie.201100265
   PubMed Web of Science ®Google Scholar
• Kuwabara I, Kuwabara Y, Yang RY, Schuler M, Green DR, Zuraw BL, Hsu DK, Liu FT. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release. J Biol Chem 2002; 277:3487-97. Epub 2001 Nov 8; PMID:11706006; http://dx.doi.org/10.1074/jbc.M109360200
   PubMed Web of Science ®Google Scholar
• Hadari YR, Arbel-Goren R, Levy Y, Amsterdam A, Alon R, Zakut R, Zick Y. Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis. J Cell Sci 2000; 113:2385-97; PMID:10852818
   PubMed Web of Science ®Google Scholar
• Hughes PE, Renshaw MW, Pfaff M, Forsyth J, Keivens VM, Schwartz MA, Ginsberg MH. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 1997; 88:521-30; PMID:9038343; http://dx.doi.org/10.1016/S0092-8674(00)81892-9
   PubMed Web of Science ®Google Scholar
• Norambuena A, Metz C, Vicuna L, Silva A, Pardo E, Oyanadel C, Massardo L, González A, Soza A. Galectin-8 induces apoptosis in Jurkat T cells by phosphatidic acid-mediated ERK1/2 activation supported by protein kinase A down-regulation. J Biol Chem 2009; 284:12670-9. Epub 2009 Mar 9; PMID:19276072; http://dx.doi.org/10.1074/jbc.M808949200
   PubMed Web of Science ®Google Scholar
• Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, Nakamura T, Hirashima M. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 2003; 170:3631-6; PMID:12646627; http://dx.doi.org/10.4049/jimmunol.170.7.3631
   PubMed Web of Science ®Google Scholar
• Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima M, et al. Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res 2010; 8:994-1001. Epub 2010 Jun 22; PMID:20571063; http://dx.doi.org/10.1158/1541-7786.MCR-10-0040
   PubMed Web of Science ®Google Scholar
• Brandlein S, Pohle T, Ruoff N, Wozniak E, Muller-Hermelink HK, Vollmers HP. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 2003; 63:7995-8005; PMID:14633732
   PubMed Web of Science ®Google Scholar
• Monzavi-Karbassi B, Artaud C, Jousheghany F, Hennings L, Carcel-Trullols J, Shaaf S, Korourian S, Kieber-Emmons T. Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J Immunol 2005; 174:7057-65; PMID:15905549; http://dx.doi.org/10.4049/jimmunol.174.11.7057
   PubMed Web of Science ®Google Scholar
• Makhoul I, Hutchins L, Emanuel PD, Pennisi A, Siegel E, Jousheghany F, et al. Moving a carbohydrate mimetic peptide into the clinic: clinical response of a breast cancer patient after mimotope-based immunotherapy. Hum Vaccin Immunother 2014; 11:1; PMID:25483551
   PubMed Web of Science ®Google Scholar
• Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, Yoshida S, Ueda R, Furukawa K. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J Biol Chem 2005; 280:29828-36. Epub 2005 May 26; PMID:15923178; http://dx.doi.org/10.1074/jbc.M414041200
   PubMed Web of Science ®Google Scholar
• Yang X, Wu L, Duan X, Cui L, Luo J, Li G. Adenovirus carrying gene encoding Haliotis discus discus sialic acid binding lectin induces cancer cell apoptosis. Mar Drugs 2014; 12:3994-4004; PMID:24983642; http://dx.doi.org/10.3390/md12073994
   PubMed Web of Science ®Google Scholar
• Hong CE, Park AK, Lyu SY. Synergistic anticancer effects of lectin and doxorubicin in breast cancer cells. Mol Cell Biochem 2014; 394:225-35. Epub 2014 May 31; PMID:24878989; http://dx.doi.org/10.1007/s11010-014-2099-y
   PubMed Web of Science ®Google Scholar
• Kieber-Emmons T, Luo P, Qiu J, Chang TY, O I, Blaszczyk-Thurin M, Steplewski Z. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat Biotech 1999; 17:660-5; http://dx.doi.org/10.1038/10870
   PubMed Web of Science ®Google Scholar
• Qiu J, Luo P, Wasmund K, Steplewski Z, Kieber-Emmons T. Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines [In Process Citation]. Hybridoma 1999; 18:103-12; PMID:10211797; http://dx.doi.org/10.1089/hyb.1999.18.103
   PubMed Web of Science ®Google Scholar
• Monzavi-Karbassi B, Hennings LJ, Artaud C, Liu T, Jousheghany F, Pashov A, Murali R, Hutchins LF, Kieber-Emmons T. Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine 2007; 25:3022-31. Epub 2007 Jan 26; PMID:17303294; http://dx.doi.org/10.1016/j.vaccine.2007.01.072
   PubMed Web of Science ®Google Scholar
• Monzavi-Karbassi B, Shamloo S, Kieber-Emmons M, Jousheghany F, Luo P, Lin KY, Cunto-Amesty G, Weiner DB, Kieber-Emmons T. Priming characteristics of peptide mimotopes of carbohydrate antigens. Vaccine 2003; 21:753-60; PMID:12531355; http://dx.doi.org/10.1016/S0264-410X(02)00703-X
   PubMed Web of Science ®Google Scholar
• Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, Somasundaram R, Ferrone S, Tsao CY, Herlyn D. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother 2008; 57:1079-89; PMID:18157673; http://dx.doi.org/10.1007/s00262-007-0439-4
   PubMed Web of Science ®Google Scholar
• Pashov A, Monzavi-Karbassi B, Kieber-Emmons T. Immune surveillance and immunotherapy: lessons from carbohydrate mimotopes. Vaccine 2009; 27:3405-15. Epub Feb 5; PMID:19200843; http://dx.doi.org/10.1016/j.vaccine.2009.01.074
   PubMed Web of Science ®Google Scholar
• Engels CC, Ruberta F, de Kruijf EM, van Pelt GW, Smit VT, Liefers GJ, Matsushima T, Shibayama M, Ishihara H, van de Velde CJ, et al. The prognostic value of apoptotic and proliferative markers in breast cancer. Breast Cancer Res Treat 2013; 142:323-39. Epub 2013 Nov 6; PMID:24194179; http://dx.doi.org/10.1007/s10549-013-2748-y
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360:790-800; PMID:19228622; http://dx.doi.org/10.1056/NEJMra0801289
   PubMed Web of Science ®Google Scholar
• Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10:R65. Epub 008 Jul 28; PMID:18662380; http://dx.doi.org/10.1186/bcr2124
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418-23. Epub 2003 Jun 26; PMID:12829800; http://dx.doi.org/10.1073/pnas.0932692100
   PubMed Web of Science ®Google Scholar
• Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005; 23:7350-60. Epub 2005 Sep 6.
   PubMed Web of Science ®Google Scholar
• Uchida N, Suda T, Ishiguro K. Effect of chemotherapy for luminal a breast cancer. Yonago Acta Med 2013; 56:51-6. Epub 2013 Jul 12; PMID:24031152
   PubMed Web of Science ®Google Scholar
• Schott AF, Hayes DF. Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30:1747-9. Epub 2012 Apr 16; PMID:22508810; http://dx.doi.org/10.1200/JCO.2011.41.3161
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384:164-72. Epub 2014 Feb 14; PMID:24529560; http://dx.doi.org/10.1016/S0140-6736(13)62422-8
   PubMed Web of Science ®Google Scholar
• Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-Tueux N, et al. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol 2015; 26:325-32. Epub 2014 Dec 1; PMID:25467016; http://dx.doi.org/10.1093/annonc/mdu551
   PubMed Web of Science ®Google Scholar
• Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 2007; 94:1189-200; PMID:17701939; http://dx.doi.org/10.1002/bjs.5894
   PubMed Web of Science ®Google Scholar
• Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366:2438-41. Epub 2012 May 30; PMID:22646508; http://dx.doi.org/10.1056/NEJMp1205737
   PubMed Web of Science ®Google Scholar
• Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, Stroyakovskiy D, Lum BL, Elliott R, Weber HA, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol 2015; 26:320-5. Epub 2014 Nov 17; PMID:25403587; http://dx.doi.org/10.1093/annonc/mdu524
   PubMed Web of Science ®Google Scholar
• Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, Justice R, Pazdur R, Cortazar P. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res 2014; 20:5359-64. Epub 2014 Sep 9; PMID:25204553; http://dx.doi.org/10.1158/1078-0432.CCR-14-1268
   PubMed Web of Science ®Google Scholar
• Overmoyer B. Treatment with adjuvant endocrine therapy for early-stage breast cancer: is it forever? J Clin Oncol 2015; 33:823-8. Epub 5 Jan 26; PMID:25624431; http://dx.doi.org/10.1200/JCO.2014.58.2361
   PubMed Web of Science ®Google Scholar
• Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res 2010; 12:204. Epub 010 Jun 8; PMID:20550729; http://dx.doi.org/10.1186/bcr2577
   PubMed Web of Science ®Google Scholar
• Schultz MJ, Swindall AF, Bellis SL. Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev 2012; 31:501-18; PMID:22699311; http://dx.doi.org/10.1007/s10555-012-9359-7
   PubMed Web of Science ®Google Scholar
• Tatsuta T, Sugawara S, Takahashi K, Ogawa Y, Hosono M, Nitta K. Cancer-selective induction of apoptosis by leczyme. Front Oncol 2014; 4:139. eCollection 2014; PMID:24926439; http://dx.doi.org/10.3389/fonc.2014.00139
   PubMedGoogle Scholar
• Tseng HH, Yu YL, Chen YL, Chen JH, Chou CL, Kuo TY, Wang JJ, Lee MC, Huang TH, Chen MH, et al. RC-RNase-induced cell death in estrogen receptor positive breast tumors through down-regulation of Bcl-2 and estrogen receptor. Oncol Rep 2011; 25:849-53. Epub 2010 Dec 20; PMID:21174060; http://dx.doi.org/10.3892/or.2010.1097
   PubMed Web of Science ®Google Scholar
• Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, Castle VP. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994; 54:3253-9; PMID:8205548
   PubMed Web of Science ®Google Scholar
• Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 2006; 12:6116-24; PMID:17062688; http://dx.doi.org/10.1158/1078-0432.CCR-06-0147
   PubMed Web of Science ®Google Scholar